BioExx Commissions Protein Isolate Facility
BioExx said that the previous concerns which were primarily caused by delays in receipt of certain valves and instruments have been resolved in all material respects allowing the
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.